Insider Selling: LifeStance Health Group (NASDAQ:LFST) Director Sells $641,250.00 in Stock

Posted by Brian Himes on May 14th, 2026

LifeStance Health Group, Inc. (NASDAQ:LFST – Get Free Report) Director Robert Bessler sold 75,000 shares of the stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $8.55, for a total value of $641,250.00. Following the completion of the transaction, the director owned 1,236,948 shares of the company’s stock, valued at $10,575,905.40. The trade was a 5.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Robert Bessler also recently made the following trade(s):

On Friday, April 24th, Robert Bessler sold 62,147 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.05, for a total value of $438,136.35.
On Thursday, April 23rd, Robert Bessler sold 7,752 shares of LifeStance Health Group stock. The shares were sold at an average price of $7.00, for a total value of $54,264.00.
On Tuesday, April 21st, Robert Bessler sold 5,101 shares of LifeStance Health Group stock. The shares were sold at an average price of $7.01, for a total value of $35,758.01.

LifeStance Health Group Stock Performance

NASDAQ:LFST opened at $8.10 on Thursday. The stock has a market cap of $3.14 billion, a P/E ratio of 135.00 and a beta of 1.20. The company has a current ratio of 1.48, a quick ratio of 1.65 and a debt-to-equity ratio of 0.18. The stock’s 50-day moving average is $6.86 and its 200-day moving average is $6.76. LifeStance Health Group, Inc. has a 1-year low of $3.74 and a 1-year high of $8.89.

LifeStance Health Group (NASDAQ:LFST – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.03. LifeStance Health Group had a net margin of 1.55% and a return on equity of 1.56%. The business had revenue of $403.48 million during the quarter, compared to analyst estimates of $387.46 million. The company’s revenue for the quarter was up 21.2% on a year-over-year basis. Equities research analysts anticipate that LifeStance Health Group, Inc. will post 0.11 earnings per share for the current year.

LifeStance Health Group declared that its Board of Directors has initiated a stock buyback plan on Wednesday, February 25th that allows the company to repurchase $100.00 million in shares. This repurchase authorization allows the company to purchase up to 3.6% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on LFST. KeyCorp lifted their price target on shares of LifeStance Health Group from $8.00 to $9.00 and gave the stock an “overweight” rating in a report on Thursday, February 26th. Barclays increased their price objective on LifeStance Health Group from $8.00 to $9.00 and gave the company an “overweight” rating in a report on Friday, March 6th. BTIG Research raised their target price on LifeStance Health Group from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Weiss Ratings raised LifeStance Health Group from a “sell (d-)” rating to a “hold (c-)” rating in a report on Friday, February 27th. Finally, Canaccord Genuity Group upped their price target on LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, LifeStance Health Group has an average rating of “Buy” and an average target price of $10.00.

Get Our Latest Stock Analysis on LifeStance Health Group

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of LFST. Larson Financial Group LLC boosted its stake in shares of LifeStance Health Group by 19,952.6% in the 4th quarter. Larson Financial Group LLC now owns 3,810 shares of the company’s stock valued at $27,000 after purchasing an additional 3,791 shares during the last quarter. KBC Group NV bought a new position in LifeStance Health Group during the first quarter worth $29,000. PNC Financial Services Group Inc. lifted its holdings in LifeStance Health Group by 615.3% in the first quarter. PNC Financial Services Group Inc. now owns 9,285 shares of the company’s stock valued at $59,000 after buying an additional 7,987 shares during the period. Assetmark Inc. lifted its holdings in LifeStance Health Group by 17.0% in the first quarter. Assetmark Inc. now owns 9,419 shares of the company’s stock valued at $60,000 after buying an additional 1,367 shares during the period. Finally, Bayesian Capital Management LP bought a new stake in LifeStance Health Group during the second quarter valued at $52,000. Institutional investors and hedge funds own 85.50% of the company’s stock.

LifeStance Health Group Company Profile

(Get Free Report)

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.